



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		<b>Complete if Known</b>			
		Application Number	10/797,626		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Filing Date	March 9, 2004		
		First Named Inventor	Peter C. Brooks		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	05986/100M228-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		
TH	AA	US-5,092,885-B1	03-03-1992	Yamada et al.	
	AB	US-5,112,946-B1	05-12-1992	Maione	
	AC	US-5,192,744-B1	03-09-1993	Bouck et al.	
	AD	US-5,202,352-B1	04-13-1993	Okada et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO 00/40597	07-13-2000	University of Southern California		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	1	Armstutz, et al., <i>In vitro</i> display technologies: novel developments and applications. Current Opinion in Biotechnology 2001;12:400-405		
	2	Blood, et al., <i>Biochim. Biophys. Acta.</i> 1990;1032:89-118		
	3	Brooks, et al., <i>J Clin. Invest.</i> 1995;96:1815-1822.		
	4	Brooks, et al., <i>Cell</i> 1994;79:1157-1164		
	5	Brooks, et al., <i>Cell</i> 1998;92:391-400		
	6	Green, et al., <i>Proc. Natl. Acad. Sci. USA</i> 2003;100:1010-1015		
	7	Guo, et al., <i>In vitro</i> evolution of amphioxus insulin-like peptide to mammalian insulin. <i>Biochemistry</i> 2002;41:10603-10607		
	8	Hangai, et al., Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. <i>American Journal of Pathology</i> 2002;161(4):1429-1437.		
	9	Heeley RP, <i>Endocr. Res.</i> 2002;28:217-229		
	10	Kurschat, et al., <i>Clin. Exp. Dermatol.</i> 2000;25:482-489		
	11	Liljeblad, et al., Analysis of agalacto-IgG in rheumatoid arthritis using surface plasmon resonance. <i>Glycoconjugate Journal</i> 2000;17:323-329		
	12	Liotta, et al., <i>Cell</i> 1991;64:327-336		
	13	Roskelley, et al., <i>Curr. Op. Cell Biol.</i> 1995;7:736-747		
	14	Stephanopoulos G, Metabolic engineering by genome shuffling. <i>Nature Biotechnology</i> 2002;20(7):666-668		
	15	Tani, et al., <i>In vitro</i> selection o fibronectin gain-of-function mutations. <i>Biochem. J.</i> 2002;365:287-294		
▼	16	Varner, et al., <i>Cell Adh. Commun.</i> 1995;3:367-374		
	17	Xu, et al., Generation of monoclonal antibodies to cryptic collagen sites by using subtractive		

W:1059 86100	Date Considered
-----------------	--------------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/797,626
				Filing Date	March 9, 2004
				First Named Inventor	Peter C. Brooks
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	05986/100M228-US1

		immunization. Hybridoma 2000;19(5)375-385	
TH	18	Xu, et al., Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. Journal of Cell Biology 2001;154(5):1069-1079	
TH	19	Weidner, et al., J. Natl. Cancer Inst. 1992;84:1875-1887	
TH	20	Weidner, et al., N. Engl. J Med. 1991;324:1-7	
TH	21	Wyckoff, et al., Cancer Res. 2000;60:2504-2511	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

W:1059 86100	/Thomas Heard/	Date Considered	12/16/2006
-----------------	----------------	--------------------	------------